BIOX Bioceres Crop Solutions

Filed: 9 Sep 21, 5:08pm





Washington, D.C. 20549


Form 6-K


Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934


For the month of September 2021


Commission File Number: 001-38836



(Translation of registrant’s name into English)


Ocampo 210 bis, Predio CCT, Rosario

Province of Santa Fe, Argentina

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.


Form 20-F  x                                                                 Form 40-F  ¨


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨







Bioceres Crop Solutions Reports

Fiscal Fourth Quarter and Full-Year 2021

Operational and Financial Results


4Q21 comparable revenues increased by 39% YoY and 13% for FY21, with LTM
Adjusted EBITDA at $48.3m, excluding HB4 contributed goods


HB4 contributed goods total $8.3m for FY21, a 295% increase YoY


Collaboration with GDM expanded to North America for HB4 Soy under shared
product development and commercialization effort


ROSARIO, Argentina – September 09, 2021 – Bioceres Crop Solutions Corp. (“Bioceres”) (NASDAQ: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported its financial results for the fiscal fourth quarter and fiscal year ended June 30, 2021. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (“YoY”), unless noted otherwise. 




·Comparable revenues up 39% to $72.4 million in the fourth quarter of fiscal 2021, with adjusted EBITDA up 13% to $16.6 million for the period. Momentum consolidated in 4Q21 confirming a very strong second half to FY21, driven predominantly by micro-beaded fertilizers sales and the reorganization of the Crop Protection business.



·HB4 Wheat planted in 55,000 hectares with contributed goods totaling $6.4 million. The value of these contributed goods will be recognized as revenues once the realized inventories are sold as seed or grain, but no longer contributed. The current multiplication area represents a 7.8X increase over last year’s effort, including varieties adapted to 75% of Argentina’s addressable market. The number of participating growers increased 8X, with 95% of participants onboarding digitally.


·HB4 Soy harvest completed in 23,000 hectares. Trait performance aligned with expectations in highly restricted environments, while germplasm drag affected performance in moderate to highly productive environments. Germplasm drag reduced to less than one third in second generation varieties when compared to first generation materials (-11% vs -3%). Experimental third generation materials showed no drag when compared to top performing commercial varieties. Average performance improved by 12% when HB4 Soy was used as second crop to wheat. As third generation materials are fast-tracked to address the broader HB4 Soy opportunity, second generation materials will be positioned in highly restricted environments and as a rotational crop to wheat until being fully replaced.







·Collaboration on HB4 Soy with Grupo Don Mario (GDM) expanded to North America with focus on the Dakotas, Minnesota and southern Canada, targeting approximately 10 million hectares highly prone to water deficits. The North America agreement contemplates a joint product development and commercialization program, focusing on maturity groups II and below. This agreement complements on-going collaboration efforts with TMG in Latin America, for maturity groups VI and above, which together with Bioceres’ on-going programs provide the full scope of maturities utilized for soy production around the globe. GDM is a global leader on soybean genetics with a growing presence in the United States. TMG is one of Brazil’s leading soybean players.


·On the regulatory front, Bioceres received approval for HB4 Soy in Canada, while no additional information was requested during the period from Chinese regulators. Regarding HB4 Wheat, regulatory approval requests were filed in Australia, New Zealand, Indonesia and South Africa, while new information was requested towards the end of the quarter by Brazil’s CTNBio. Additional data was produced to address CTNBio’s request and filed subsequent to the quarter´s end.




·Comparable revenues up 13% to $197.4 million compared to the year-ago period. Revenue growth across all three segments despite softer performance in second quarter due to climate challenges in key markets. Growth mainly driven by the deployment of the micro-beaded fertilizers expansion plan and 4Q Crop protection reorganizational strategy.


·Contributed goods for HB4 Program, both HB4 Wheat and HB4 Soy, increased significantly to $8.3 million (approximately $105 per hectare farmed) with an average gross margin of approximately 43%. The value of these contributed goods will be recognized as revenues once the realized inventories are sold as seed or grain, but no longer contributed.


·Bioceres’ drought tolerant HB4 Wheat was commercially approved in Argentina on October 2020, subject to Brazilian import approval, Argentina’s main wheat importer. This approval represents a historical milestone for the entire global value chain being the first biotech wheat cleared.


·Bioceres acquired from Arcadia Biosciences Inc. the remaining HB4 Soy ownership interest in Verdeca LLC, targeting to accelerate breeding and go-to market strategies. Complete ownership will also enable Bioceres to capture more of the underlying economic value generated by the technology. As part of the transaction, the Company acquired Verdeca´s vetted soybean library of gene-edited materials for developing new quality and productivity traits, as well as exclusive rights to all Arcadia technologies applicable to this crop. Bioceres has also been granted Latin American rights to Arcadia’s wheat traits and Good Wheat® brand and other GLA non-core assets.







·Successful completion of the Offer to Exchange of all 24,200,000 outstanding warrants, cost effectively eliminating uncertainty about how these instruments could have affect our future capital structure.


·$71.5 million total financing obtained during FY21. $43.0 million of funding was added through Rizobacter’s series IV & V corporate bonds, continuing to make considerable progress toward substantially lowering financing costs, extending debt maturities and increasing financial flexibility. $28.5 million equity financing completed through the aforementioned Verdeca’s acquisition and the warrants tender offer transaction.




Commenting on the Company’s performance Mr. Federico Trucco, Chief Executive Officer of Bioceres, said, “We are very pleased with the performance of our business during FY21 on multiple fronts. The second half of FY21 was particularly important after the drop we experienced in the second quarter, historically our most important quarter. We are beginning to see the benefits of our new strategies in the crop nutrition and crop protection segments, as we continue to scale and finetune our HB4 roll-out. We expect the momentum of this second half to continue during FY22.”


Mr. Enrique Lopez Lecube, Chief Financial Officer of Bioceres, said, “The fourth quarter was a great closing to the year. During fiscal 2021 the base-line business continued to deliver profitable growth, as we also made progress in rolling out HB4. Importantly, a total of $71.5 million of capital were raised through debt and equity instruments that provided financial support to our operations and investment activities. Liquidity in our stock improved significantly over the year, and remains a priority to management as we aim for more ambitious levels of trading activity.” 


Key Operational Metrics (Figures in millions of US dollars, unless otherwise noted)


Table 1: HB4 Wheat Metrics

Hectares  GrowersContributed goods1

FY20 7,000

FY21 55,000


FY20 25

FY21 225


FY20 1.4M

FY21 6.4M




1Metric will be used to account for and track the underlying economic performance of our HB4 Wheat and HB4 Soy Program ahead of reporting HB4 revenues and related accounting measures. By publishing the level of contributed goods, the investment community can also use this information to better gauge our progress.







Table 2: HB4 Soy Metrics

Hectares  GrowersContributed goods1

FY20 3,000

FY21 23,000


FY20 15

FY21 148


FY20 0.7M

FY21 1.9M



Table 3: Key Financial Metrics (Figures in millions of US dollars, unless otherwise noted)


4Q21  As Reported   % Change 
Revenue by Segment  4Q20  4Q21  Reported   Comparable¹ 
Crop Protection  26.5   48.1   81%  48%
Seed and Integrated Products  6.0   10.0   66%  (8)%
Crop Nutrition  15.7   24.1   54%  46%
Total Revenue  48.2   82.2   71%  39%
Gross Profit  22.8   32.4   42%  28%
Gross Margin  47.4%  39.4%  (796)bps  (384)bps
Adjusted EBITDA  14.7   16.6   13%    
Adjusted EBITDA Margin  30.5%  20.2%  (1,032)Bps    


1.Comparable excludes the impact of IAS29 as discussed in more detail on page 19 of the full version of Bioceres Fiscal Fourth Quarter and Full Fiscal Year 2021 Earnings Release.







Table 4: Key Financial Metrics (Figures in millions of US dollars, unless otherwise noted)


Full Fiscal Year Period As Reported  % Change 
Revenue by Segment FY20  FY21  Reported  Comparable¹ 
Crop Protection  94.2   114.1   21%  13%
Seed and Integrated Products  29.5   34.8   18%  5%
Crop Nutrition  49.4   60.6   23%  19%
Total Revenue  173.1   209.5   21%  13%
Gross Profit  79.5   90.6   14%  11%
Gross Margin  45.9%  43.3%  (268)bps  (102)bps
Adjusted EBITDA  46.5   48.3   4%    
Adjusted EBITDA Margin  26.9%  23.0%  (383)Bps    
Cash & Cash Equivalents  56.0   49.2         
Net Debt to LTM EBITDA  1.98x  2.51x        


1.Comparable excludes the impact of IAS29 as discussed in more detail on page 19 of the full version of Bioceres Fiscal Fourth Quarter and Full Fiscal Year 2021 Earnings Release.


For a full version of Bioceres Fiscal Fourth Quarter and Full Fiscal Year 2021 Earnings Release, click here.




Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Máximo Goya will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the company’s website here.


To access the call, please use the following information:


Date:Thursday, September 9, 2021
Time:8:30 a.m. EDT, 5:30 a.m. PDT
Toll Free dial-in number:1-844-839-9680
Toll/International dial-in number:             1-647-689-2346
Conference ID:1936609
Pre-Register conference call:Click here







Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.


The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.


A replay of the call will be available until September 14, 2021 following the conference.


Toll Free Replay Number:1-800-585-8367
International Replay Number:1-416-621-4642
Replay ID:1936609


About Bioceres Crop Solutions Corp.


Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.




Investor Relations Contact
Chris Tyson

Executive Vice President

MZ Group – MZ North America 
(949) 491-8235


Bioceres Crop Solutions

Máximo Goya, Head of Investor Relations







Forward-Looking Statements


This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law. 


Unaudited Consolidated Statement of Comprehensive Income (Figures in US dollars)


  Three-month  Three-month  Fiscal year  Fiscal year 

period ended


  period ended
Total revenue  82,211,114   48,173,814   209,526,178   173,092,172 
Cost of sales  (49,802,175)  (25,347,698)  (118,890,568)  (93,575,588)
Gross profit  32,408,939   22,826,116   90,635,610   79,516,584 
% Gross profit  39%  47%  43%  46%
Operating expenses  (17,917,721)  (11,277,602)  (53,025,090)  (42,540,298)
Share of profit of JV  (214,499)  1,310,768   997,429   2,477,193 
Other income or expenses, net  (625,418)  (103,835)  (279,969)  (307,499)
Operating profit  13,651,301   12,755,447   38,327,980   39,145,980 
Finance result  (3,821,662)  (8,249,014)  (27,462,000)  (32,702,642)
Profit before income tax  9,829,639   4,506,433   10,865,980   6,443,338 
Income tax  (8,041,797)  (1,368,437)  (14,273,960)  (2,206,710)
Profit/ (Loss) for the period  1,787,842   3,137,996   (3,407,980)  4,236,628 
Other comprehensive profit / (loss)  4,865,362   (2,058,672)  7,572,426   (9,682,116)
Total comprehensive Profit / (Loss)  6,653,204   1,079,324   4,164,446   (5,445,488)
Profit / (loss) for the period attributable to:                
Equity holders of the parent  901,804   2,215,404   (6,602,045)  3,359,175 
Non-controlling interests  886,038   922,592   3,194,065   877,453 
   1,787,842   3,137,996   (3,407,980)  4,236,628 
Total comprehensive income / (loss) attributable to:                
Equity holders of the parent  4,724,172   375,178   (554,774)  (5,222,572)
Non-controlling interests  1,929,032   704,146   4,719,220   (222,916)
   6,653,204   1,079,324   4,164,446   (5,445,488)







Unaudited Consolidated Statement of Financial Position (Figures in US dollars)


ASSETS 06/30/2021  06/30/2020 
Cash and cash equivalents  35,873,746   42,522,861 
Other financial assets  13,334,452   13,436,393 
Trade receivables  83,587,511   73,546,633 
Other receivables  12,181,943   4,770,672 
Income and minimum presumed income taxes recoverable  990,881   112,220 
Inventories  61,037,552   29,338,548 
Biological assets 2,315,838  965,728 
Total current assets  209,321,923   164,693,055 
Other financial assets  1,062,453   322,703 
Trade receivables  135,739   - 
Other receivables  2,403,608   1,703,573 
Income and minimum presumed income taxes recoverable  12,589   6,029 
Deferred tax assets  3,125,841   2,693,195 
Investments in joint ventures and associates  30,657,173   24,652,792 
Property, plant and equipment  47,954,596   41,515,106 
Intangible assets  67,342,362   35,333,464 
Goodwill  26,684,090   25,526,855 
Right-of-use leased asset  1,327,660   1,114,597 
Total non-current assets  180,706,111   132,868,314 
Total assets  390,028,034   297,561,369 






Trade and other payables  72,803,496   57,289,862 
Borrowings  73,832,610   63,721,735 
Employee benefits and social security  4,680,078   4,510,592 
Deferred revenue and advances from customers  6,277,313   2,865,437 
Income tax payable  7,194,761   1,556,715 
Government grants  784   1,270 
Lease liabilities  750,308   665,098 
Total current liabilities  165,539,350   130,610,709 
Borrowings  47,988,461   41,226,610 
Employee benefits and social security  -   534,038 
Government grants  -   2,335 
Investments in joint ventures and associates  1,278,250   1,548,829 
Deferred tax liabilities  25,823,281   16,858,125 
Provisions  449,847   417,396 
Consideration for acquisitions  11,828,487   - 
Warrants  -   1,686,643 
Convertible notes  48,664,012   43,029,834 
Lease liability  390,409   444,714 
Total non-current liabilities  136,422,747   106,201,178 
Total liabilities 301,962,097   236,811,887 
Equity attributable to owners of the parent  65,629,762   46,179,395 
Non-controlling interests  22,436,175   14,570,087 
Total equity  88,065,937   60,749,482 
Total equity and liabilities  390,028,034   297,561,369 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated: September 9, 2021By:By:/s/ Federico Trucco
  Name:Federico Trucco
  Title:Chief Executive Officer